Zai Lab's Drug Receives Orphan Status for Rare Cancer Treatment

Zai Lab has been granted orphan drug status for its investigational treatment targeting pulmonary neuroendocrine carcinomas, which is significant due to the rarity of this cancer type. This designation will facilitate the development and regulatory process for the drug, potentially leading to new treatment options for patients with limited alternatives. It highlights the ongoing efforts to address unmet medical needs in oncology.